239 related articles for article (PubMed ID: 16522576)
1. The costs of scaling up vaccination in the world's poorest countries.
Bishai D; McQuestion M; Chaudhry R; Wigton A
Health Aff (Millwood); 2006; 25(2):348-56. PubMed ID: 16522576
[TBL] [Abstract][Full Text] [Related]
2. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
Peny JM; Gleizes O; Covilard JP
Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
[TBL] [Abstract][Full Text] [Related]
3. Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability?
Lydon P; Levine R; Makinen M; Brenzel L; Mitchell V; Milstien JB; Kamara L; Landry S
Vaccine; 2008 Dec; 26(51):6706-16. PubMed ID: 18952134
[TBL] [Abstract][Full Text] [Related]
4. Strategies for financial sustainability of immunization programs: a review of the strategies from 50 national immunization program financial sustainability plans.
Kamara L; Milstien JB; Patyna M; Lydon P; Levin A; Brenzel L
Vaccine; 2008 Dec; 26(51):6717-26. PubMed ID: 18955100
[TBL] [Abstract][Full Text] [Related]
5. Incremental system costs of introducing combined DTwP-hepatitis B-Hib vaccine into national immunization services in Ethiopia.
Griffiths UK; Korczak VS; Ayalew D; Yigzaw A
Vaccine; 2009 Feb; 27(9):1426-32. PubMed ID: 19146901
[TBL] [Abstract][Full Text] [Related]
6. Effect of the Global Alliance for Vaccines and Immunisation on diphtheria, tetanus, and pertussis vaccine coverage: an independent assessment.
Lu C; Michaud CM; Gakidou E; Khan K; Murray CJ
Lancet; 2006 Sep; 368(9541):1088-95. PubMed ID: 16997663
[TBL] [Abstract][Full Text] [Related]
7. Financial challenges of immunization: a look at GAVI.
Kaddar M; Lydon P; Levine R
Bull World Health Organ; 2004 Sep; 82(9):697-702. PubMed ID: 15628208
[TBL] [Abstract][Full Text] [Related]
8. The immunization data quality audit: verifying the quality and consistency of immunization monitoring systems.
Ronveaux O; Rickert D; Hadler S; Groom H; Lloyd J; Bchir A; Birmingham M
Bull World Health Organ; 2005 Jul; 83(7):503-10. PubMed ID: 16175824
[TBL] [Abstract][Full Text] [Related]
9. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
10. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries.
Atherly D; Dreibelbis R; Parashar UD; Levin C; Wecker J; Rheingans RD
J Infect Dis; 2009 Nov; 200 Suppl 1():S28-38. PubMed ID: 19817610
[TBL] [Abstract][Full Text] [Related]
11. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
Goldie SJ; O'Shea M; Diaz M; Kim SY
Reprod Health Matters; 2008 Nov; 16(32):86-96. PubMed ID: 19027626
[TBL] [Abstract][Full Text] [Related]
12. Combinations, the key to global immunization.
CVI Forum; 1993 Nov; (5):2-6. PubMed ID: 12294217
[TBL] [Abstract][Full Text] [Related]
13. Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in kyrgyzstan.
Flem ET; Latipov R; Nurmatov ZS; Xue Y; Kasymbekova KT; Rheingans RD
J Infect Dis; 2009 Nov; 200 Suppl 1():S195-202. PubMed ID: 19817600
[TBL] [Abstract][Full Text] [Related]
14. Economic analyses of rubella and rubella vaccines: a global review.
Hinman AR; Irons B; Lewis M; Kandola K
Bull World Health Organ; 2002; 80(4):264-70. PubMed ID: 12075361
[TBL] [Abstract][Full Text] [Related]
15. GAVI and the Vaccine Fund--a boon for immunization in the developing world.
Balaji KA
Indian J Public Health; 2004; 48(2):45-8. PubMed ID: 15709583
[TBL] [Abstract][Full Text] [Related]
16. Design and simulation study of the immunization Data Quality Audit (DQA).
Woodard S; Archer L; Zell E; Ronveaux O; Birmingham M
Ann Epidemiol; 2007 Aug; 17(8):628-33. PubMed ID: 17553701
[TBL] [Abstract][Full Text] [Related]
17. Costs of vaccine programs across 94 low- and middle-income countries.
Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
[TBL] [Abstract][Full Text] [Related]
18. Boostrix: a reduced-dose acellular pertussis vaccine for use in adolescents and adults.
Li WC; Wu TZ; Huang YC; Huang LM
Expert Rev Vaccines; 2009 Oct; 8(10):1317-27. PubMed ID: 19803753
[TBL] [Abstract][Full Text] [Related]
19. Costs of polio immunization days in China: implications for mass immunization campaign strategies.
Zhang J; Yu JJ; Zhang RZ; Zhang XL; Zhou J; Wing JS; Schnur A; Wang KA
Int J Health Plann Manage; 1998; 13(1):5-25. PubMed ID: 10178584
[TBL] [Abstract][Full Text] [Related]
20. [Cost of tetanus toxoid injection using a jet-injector (Imule) in collective immunization in Senegal: comparison with injection using a syringe and resterilizable needle].
Schlumberger M; Châtelet IP; Lafarge H; Genêt A; Gaye AB; Monnereau A; Sanou C; Diawara L; Gueye Y; Lang J
Sante; 1999; 9(5):319-26. PubMed ID: 10657777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
